SCHEMBL31532117

SCHEMBL31532117

CC(C)Nc1ncc2cc(Br)c(=O)[nH]c2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK4 P11802 1/20 0.40
▸ CCND1 P24385 1/20 0.40
▸ CCND2 P30279 1/20 0.40
▸ CCND3 P30281 1/20 0.40
▸ IGF1R P08069 2/20 0.39
▸ MAPK8 P45983 4/20 0.39
▸ FGFR1 P11362 2/20 0.39
▸ KDR P35968 2/20 0.39
▸ MAPK9 P45984 2/20 0.39
▸ CHEK1 O14757 1/20 0.39
▸ AURKA O14965 1/20 0.39
▸ DAPK3 O43293 1/20 0.39
▸ PRKD3 O94806 1/20 0.39
▸ MAP4K4 O95819 1/20 0.39
▸ LCK P06239 1/20 0.39
▸ FYN P06241 1/20 0.39
▸ CSF1R P07333 1/20 0.39
▸ RET P07949 1/20 0.39
▸ PDGFRB P09619 1/20 0.39
▸ LTK P29376 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22612785 0.83 SIK2 (0.45) FGFR1AURKAAURKBDYRK1BIDH1
SCHEMBL31532055 0.83 SIK2 (0.45) FGFR1AURKAAURKBDYRK1BIDH1
SCHEMBL31532076 0.79 CDK4 (0.42) CDK4CCND1CCND2CCND3IGF1R
SCHEMBL29861753 0.76 PDK2 (0.39) FGFR1KDRAURKADAPK3PRKD3
SCHEMBL255621 0.75 MEN1 (0.46) CDK4CCND1CCND2CCND3IGF1R
SCHEMBL31532080 0.75 MAPK14 (0.47) CDK4CCND1CCND2CCND3IGF1R
SCHEMBL15280148 0.74 CDC7 (0.38) FGFR1KDRAURKADAPK3PRKD3
SCHEMBL17910166 0.74 MAPK8 (0.54) CDK4CCND1CCND2CCND3IGF1R
SCHEMBL29538008 0.73 MEN1 (0.38) ALDH1A1
SCHEMBL661610 0.73 MEN1 (0.38) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025043349-A1 PYRIMIDOPYRIDONE AND PTERIDONE DERIVATIVES AS INHIBITORS OF THE GCN2 KINASE, COMPOSITIONS AND USES THEREOF ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2025-03-06 — — WO disclosed
Send feedback